11 results about "Aggrecan" patented technology

The invention belongs to the technical field of biological medicine, and particularly relates to a HA / CS / dECM-AD hydrogel medicine and application thereof in treatment of osteoarthritis, the hydrogel medicine is composed of a three-dimensional network composed of hyaluronic acid (HA), chitosan (CS) and a decellularized extracellular matrix (dECM), and two active ingredients of atorvastatin (Ato) and docosapentaenoic acid (DPA) are loaded in the three-dimensional network. The hydrogel has the following characteristics: a dual slow-release mechanism is adopted, Ato is quickly released within 2 hours, and DPA is accumulatively released by 70-90% within 7 days through PDA nanoparticles; according to biological activity induction, the dECM derived from hiPSCs retains cartilage specific components such as type II collagen (COL2) and aggregation protein glycan (ACAN), and cartilage cell proliferation is promoted; and the retention time in the articular cavity exceeds 6 weeks. Animal experiments show that the hydrogel can remarkably repair cartilage defects, inhibit M1 type macrophage infiltration and reduce expression of proinflammatory factors such as IL-1beta and TNF-alpha.

To provide: immunoglobulins that specifically bind to aggrecan, and particularly polypeptides and nucleic acids encoding such polypeptides; methods for preparing such polypeptides; and compositions, particularly pharmaceutical compositions, that comprise such polypeptides for prophylactic, therapeutic or diagnostic purposes.SOLUTION: In particular, the immunoglobulins of the present invention inhibit the activity of aggrecan.SELECTED DRAWING: None

The invention belongs to the technical field of biological medicines, and particularly discloses application of low-concentration recombinant human periostin in preparation of a medicine for treating intervertebral disc degeneration. The invention provides application of low-concentration recombinant human periostin in preparation of a medicine for treating intervertebral disc degeneration. The invention provides application of low-concentration recombinant human periostin in preparation of a medicine for treating intervertebral disc degeneration. The low-concentration recombinant human periostin can remarkably reduce the death rate of intervertebral disc nucleus pulposus cells induced by TNF-alpha, effectively relieve oxidative stress injury, up-regulate the expression of Collagen II and Aggrecan, down-regulate the expression of MMP 13, promote cell proliferation and treat intervertebral disc degeneration.

The invention discloses a traditional Chinese medicine formula self-assembled nanoparticle for treating intervertebral disc degeneration. The nanoparticle is prepared by decocting 30 parts by weight of astragalus membranaceus, 15 parts by weight of angelica sinensis, 15 parts by weight of morinda officinalis, 15 parts by weight of achyranthes bidentata, 10 parts by weight of rhizoma alismatis, 20 parts by weight of rhizoma cibotii and 6 parts by weight of radix saposhnikoviae with water, concentrating, performing gradient centrifugation, performing ultracentrifugation, performing filter membrane grading and freeze-drying to prepare core-shell structure nano freeze-dried powder which is about 180nm, has negative electricity on the surface and is stable at pH of 2-12. And nucleus pulposus matrix metabolism imbalance, inflammation and pyroptosis can be synchronously intervened. After the tendon and bone strengthening nano-particles are injected into the intervertebral disc for a single time, the intervertebral disc can be locally retained for 4 weeks, COL2 and Aggrecan are remarkably up-regulated, pyroptosis mediated by MMP13, ADAMTS5 and NLRP3-GSDMD is inhibited, height loss and structural damage of the intervertebral disc are reversed, the curative effect is superior to that of a traditional decoction, and no obvious toxic or side effect exists.

The present invention provides a use of a ugonin compound for the treatment of joint-related diseases by enhancing chondrogenesis. More specifically, the chondrogenesis is mediated by the ugonin compound’s ability to promote the increase of aggrecan and type II collagen, which is achieved through the inhibition of miR-3074-5p and the activation of the MAPK signaling pathway.

The invention discloses a CD24 positive nucleus pulposus progenitor cell for inhibiting nucleus pulposus cell ferroptosis, a pharmaceutical composition and application. The invention firstly protects an isolated CD24 + NPPCs population and a pharmaceutical composition thereof. The invention protects the application of the cell population and the pharmaceutical composition in preparation of drugs for inhibiting nucleus pulposus cell ferroptosis and / or improving intervertebral disc degeneration microenvironment. The nucleus pulposus progenitor cell subgroup is enriched and obtained by taking CD24 as a marker. Experiments prove that the cell population can play a role through a multiple synergistic mechanism: on one hand, the ferroptosis of nucleus pulposus cells is effectively inhibited by up-regulating proteins such as GPX4 and SLC7A11 and reducing lipid peroxidation; on the other hand, by reducing the level of proinflammatory factors such as TNF-alpha and promoting synthesis of extracellular matrixes such as Aggrecan and COL2A1, the healthy intervertebral disc microenvironment is remodeled, and tissue regeneration is promoted.

A processed human umbilical cord composition for treating Peyronie's disease by intracorporeal injection of an effective amount into a subject in need thereof, the composition comprising an aqueous human umbilical cord filtrate containing endogenous hyaluronic acid (HA) and / or hyaluronan, fibronectin, insulin growth factor binding protein-1 (IGFBP-1), sulfated glycosaminoglycans (sGAGs), exosomes, interleukin-1 receptor antagonist (IL-1ra), hepatocyte growth factor (HGF), transthyretin, tissue inhibitor of metalloproteinase 1 (TIMP-1), aggrecan, or a combination thereof, in an amount effective to reduce the size of Peyronie's disease plaques.

The invention belongs to the technical field of cream, and particularly relates to slow-release cream suitable for joint maintenance and a preparation method and application thereof. The sustained-release cream suitable for joint maintenance is prepared from the following components in percentage by mass: 0.5 to 1.7 percent of dimethyl sulfone, 8 to 10 percent of soluble proteoglycan, 1 to 1.5 percent of sodium chondroitin sulfate, 5 to 8 percent of modified glucosamine, 1 to 3 percent of oligopeptide, 1 to 3 percent of protein hydrolysate, 1.5 to 3.5 percent of transdermal enhancer, 6 to 8 percent of grease, 4 to 8 percent of emulsifier, 12 to 15 percent of humectant, 1 to 3 percent of thickener, 0.1 to 0.5 percent of antioxidant, 1 to 3 percent of lecithin and the balance of deionized water. The cream provided by the invention is suitable for daily maintenance of joint parts, and research shows that the cream can improve the expression level of aggregation proteoglycan in human immortalized keratinocytes, improve the local sensible temperature of joints and has the effect of relieving joint discomfort.

The invention discloses injectable bioactive matrix hydrogel with an anti-angiogenesis and anti-neurogenesis microenvironment and application of the injectable bioactive matrix hydrogel. The injectable bioactive matrix hydrogel is prepared from bevacizumab, a concentrated growth factor and methacrylic acid chondroitin sulfate. The hydrogel prepared by the invention not only shows excellent injectability and biocompatibility, but also can inhibit pathological vascularization and neurogenesis, polarize macrophages to promote regeneration of M2 phenotype so as to relieve inflammation, and directly enhance deposition of cartilage specific ECM components (such as type II collagen and aggregation proteoglycan). By utilizing the coordinated multi-mechanism strategy, the comprehensive structure and function repair of the degenerated intervertebral disc is realized.

The present invention relates to a composition for the prevention or treatment of rheumatoid arthritis, comprising, as an active ingredient, a supercritical extract of Acanthopanax sessiliflorus Harms. In the present invention, it was confirmed that, upon administration of the supercritical extract of Acanthopanax sessiliflorus Harms to a rheumatoid arthritis animal model, pain induced by rheumatoid arthritis was reduced and cartilage damage was suppressed. Also, a decrease in the infiltration of immune cells in cartilage tissue was confirmed, and it was confirmed that the expression of Col2a1, Sox9, and Aggrecan, which are cartilage anabolic factors whose expression is reduced by inflammatory cytokines and inflammatory factors, was increased, and the expression of Mmp3, Mmp10, Mmp13, and Adamts5, which are cartilage catabolic factors, was reduced. It was also confirmed that pimaric acid and kaurenoic acid, which are useful components of the supercritical extract of Acanthopanax sessiliflorus Harms, protected chondrocytes and suppressed the differentiation of Th17 cells, which are pathogenic cells in rheumatoid arthritis.